Product Information
TERBINAFINE HCL 250 MG TABLET is a generic product labeled by Cipla USA Inc., priced at $0.1513 per EA under NDC 69097073102. Its NADAC has been published 219 times since Feb 24, 2021.
Strength
250 mg/1
Manufacturer
Cipla USA Inc.NDC
69097073102
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Last Updated
4/23/2025
Active Ingredients
TERBINAFINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA077137On Market Since
1/8/2021
Pharmacological Classes
Price Statistics
The NADAC for TERBINAFINE HCL 250 MG TABLET has been published 219 times since Feb 24, 2021, and over the history we have for it it has declined 8.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1513 per EA |
|---|---|
| All-time high | $0.1777 (Aug 11, 2021) |
| All-time low | $0.1158 (Nov 20, 2024) |
| Median price | $0.1562 |
| Average price | $0.1544 |
| Largest weekly change | -21.1% (Nov 20, 2024) |
| Weeks tracked | 219 |
| Tracking since | Feb 24, 2021 |
Generic Alternatives
The matcher finds 1 NADAC-published product sharing this drug's active ingredient, strength, and dosage form across 1 manufacturer (up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Frequently asked questions
What is the NADAC price of TERBINAFINE HCL 250 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for TERBINAFINE HCL 250 MG TABLET, manufactured by Cipla USA Inc., is $0.1513 per EA (NDC 69097073102), effective Apr 30, 2025.
How has the price of TERBINAFINE HCL 250 MG TABLET changed over time?
Over the history we have for it, the NADAC for TERBINAFINE HCL 250 MG TABLET has declined 8.6%. It has been tracked across 219 weekly CMS publications since Feb 24, 2021.
What are the highest and lowest recorded NADAC prices for TERBINAFINE HCL 250 MG TABLET?
Since Feb 24, 2021, the NADAC for TERBINAFINE HCL 250 MG TABLET has ranged from a low of $0.1158 (Nov 20, 2024) to a high of $0.1777 (Aug 11, 2021), with a median of $0.1562 per EA.
Are there cheaper alternatives to TERBINAFINE HCL 250 MG TABLET?
1 NADAC-published product shares the same active ingredient, strength, and dosage form as TERBINAFINE HCL 250 MG TABLET, but none are currently priced below it.
Who manufactures TERBINAFINE HCL 250 MG TABLET?
TERBINAFINE HCL 250 MG TABLET (NDC 69097073102) is labeled by Cipla USA Inc., and CMS classifies it as a generic product.
Related Drugs
Same classification